Want to see CLBT full AI Analyst Report?
CLBT Stock Chart & Stats
$13.18
-$0.01(-0.05%)
At close: 4:00 PM EST
$13.18
-$0.01(-0.05%)
Day’s Range― - ―
52-Week Range$11.02 - $19.98
Previous CloseN/A
Volume262.11K
Average Volume (3M)1.93M
Market Cap
$4.04B
Enterprise Value$3.07K
Total Cash (Recent Filing)$429.07M
Total Debt (Recent Filing)$22.80M
Price to Earnings (P/E)54.2
Beta0.77
Next Earnings
Aug 12, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding249,439,820
10 Day Avg. Volume1,842,063
30 Day Avg. Volume1,931,478
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)9.41
Price to Sales (P/S)9.58
P/FCF Ratio29.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$19.75Price Target Upside49.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.37
Revenue Forecast (FY)$567.97M
Bulls Say, Bears Say
Bulls Say
High Margins And Strong Free Cash FlowCellebrite’s very high gross margin and sizable trailing‑twelve‑month free cash flow support durable profitability and internal reinvestment. Strong cash conversion (~0.92 FCF to earnings) and operating cash buffer provide flexibility for R&D, product launches, and disciplined M&A without stressing the balance sheet.
Recurring Revenue Model With ARR MomentumA subscription/ARR business model increases revenue predictability and expandability via renewals and upsells. Recent ARR growth and explicit ARR guidance indicate healthy subscription momentum, which supports multi‑year revenue visibility and higher lifetime customer value versus one‑time sales.
Product Expansion: AI Traction And Large Investigative AI TAMEarly adoption of agentic AI (Genesis) and GA of Guardian Investigate target a sizable $12.5B TAM, creating a structural growth runway. If the company converts adoption into monetized ARR, these platform extensions can sustainably expand average revenue per customer and create differentiated competitive positioning.
Bears Say
Recent Slowdown In Reported Revenue GrowthA marked deceleration in trailing revenue growth signals potential saturation, timing issues, or mix shifts that could hinder multi‑period topline expansion. Sustained recovery depends on converting new products and regions into recurring revenue, so this trend raises medium‑term execution demands on sales and product teams.
Execution Risk Converting AI/product Adoption Into RevenueWhile product adoption is encouraging, monetization and scalable deployment are uncertain. Failure to price, package, or integrate AI offerings at scale could stall ARR expansion, compress margins, and delay ROI on development and go‑to‑market investments, making near‑term traction fragile.
Near‑term Leadership Transition In Product/technologyA senior product leadership change during major product launches raises change‑management risk. Even with an internal successor, transitions can slow decision making, disrupt product roadmaps, or weaken execution cadence at a critical time for AI rollout and platform integrations, impacting medium‑term delivery.
CLBT FAQ
What was Cellebrite Di Ltd.’s price range in the past 12 months?
Cellebrite Di Ltd. lowest stock price was $11.02 and its highest was $19.98 in the past 12 months.
What is Cellebrite Di Ltd.’s market cap?
Cellebrite Di Ltd.’s market cap is $4.04B.
When is Cellebrite Di Ltd.’s upcoming earnings report date?
Cellebrite Di Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 26 days.
How were Cellebrite Di Ltd.’s earnings last quarter?
Cellebrite Di Ltd. released its earnings results on May 14, 2026. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.054 by -$0.014.
Is Cellebrite Di Ltd. overvalued?
According to Wall Street analysts Cellebrite Di Ltd.’s price is currently Undervalued.
Does Cellebrite Di Ltd. pay dividends?
Cellebrite Di Ltd. does not currently pay dividends.
What is Cellebrite Di Ltd.’s EPS estimate?
Cellebrite Di Ltd.’s EPS estimate is 0.06.
How many shares outstanding does Cellebrite Di Ltd. have?
Cellebrite Di Ltd. has 249,439,820 shares outstanding.
What happened to Cellebrite Di Ltd.’s price movement after its last earnings report?
Cellebrite Di Ltd. reported an EPS of $0.04 in its last earnings report, missing expectations of $0.054. Following the earnings report the stock price went up 8.43%.
Which hedge fund is a major shareholder of Cellebrite Di Ltd.?
Currently, no hedge funds are holding shares in CLBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cellebrite DI Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (49.85% Upside)
$19.75 (49.85% Upside)
Blogger Sentiment
Bullish
CLBT Sentiment 70%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Decreased
By 198.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.08%
12-Months-Change
Fundamentals
Return on Equity
15.53%
Trailing 12-Months
Asset Growth
34.15%
Trailing 12-Months
Company Description
Cellebrite Di Ltd.
Cellebrite DI Ltd. delivers specialized digital intelligence solutions crafted for legally authorized investigations. Their comprehensive DI platform enables users to efficiently gather, scrutinize, interpret, and oversee digital information throughout the investigative process. These essential tools are utilized in a wide array of scenarios, including cases involving child exploitation, homicides, counter-terrorism operations, border control, sexual offenses, human trafficking, corporate security incidents, intellectual property theft, and civil litigation. A key offering, the Universal Forensic Extraction Device (UFED), is engineered to surmount significant hurdles in accessing digital evidence, such as intricate device locks, encryption barriers, deleted data, and obscure content that might otherwise conceal crucial information. The company also provides Seeker, designed for analyzing video footage; OSINT Analyze, a real-time deep-dive tool for examining open-source information across the surface, deep, and dark web; and Crypto Tracer, which deciphers blockchain transactions alongside related data from numerous sources to identify and categorize digital wallets and activities. Cellebrite's clientele includes federal, state, and local government bodies, as well as various enterprise companies and service providers. Established in 1999 and headquartered in Petah Tikva, Israel, the firm operates internationally with a footprint in countries such as the United States, Germany, Singapore, Australia, Brazil, the United Kingdom, France, Canada, Japan, and India. Additionally, Cellebrite Mobile Synchronization Ltd. functions as a subsidiary of Sun Corporation.
CLBT Stock 12 Month Forecast
Average Price Target
$19.75
▲(49.85% Upside)
Technical Analysis
Ownership Overview
0.77% Insiders
7.77% Mutual Funds
0.03% Other Institutional Investors
89.55% Public Companies and
Individual Investors










